Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS status confers therapeutic sensitivity to Cetuximab, Irinotecan in patients with Colorectal Adenocarcinoma.
The European Medicines Agency (EMA) has authorized cetuximab in combination with irinotecan-based chemotherapy for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer.
This statement is based on a regulatory approval from the European Medicines Agency:
Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in combination with irinotecan-based chemotherapy.